Movement disorders News and Research

RSS

Researchers identify high levels of certain protein in brains of people suffering from essential tremor

A team of researchers from Universit- Laval and CHU de Qu-bec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population.

5 Mar 2014

Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

For people whose hands shake uncontrollably due to a medical condition, just eating can be a frustrating and embarrassing ordeal - enough to keep them from sharing a meal with others.

3 Mar 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

FAST-MAG clinical trial finds that magnesium does not improve stroke-related disability

In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of symptom onset does not improve stroke outcomes, according to research presented today at the American Stroke Association's International Stroke Conference.

14 Feb 2014

UCLA researchers awarded $6M grant to explore new therapies for spinal-cord injuries

The National Institute of Biomedical Imaging and Bioengineering has awarded UCLA researchers Dr. Daniel Lu (Brentwood) and Dr. Reggie Edgerton (Bel Air) a $6 million, five-year grant to explore new therapies for the approximately 273,000 Americans living with spinal-cord injuries. Some 12,000 Americans suffer such injuries each year.

10 Feb 2014

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms.

5 Feb 2014

Magnetoencephalography can be used to control and train specific targeted brain regions

A new brain-imaging technique enables people to 'watch' their own brain activity in real time and to control or adjust function in pre-determined brain regions. The study from the Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, published in NeuroImage, is the first to demonstrate that magnetoencephalography can be used as a potential therapeutic tool to control and train specific targeted brain regions.

21 Jan 2014

GLNT study to evaluate abnormal muscle tone caused by neurological disorders

Great Lakes NeuroTechnologies announced today that it is launching a study to determine the feasibility of a clinician-worn glove to objectively evaluate abnormal muscle tone, such as stiff joints or muscle tightness, due to neurological disorders.

16 Jan 2014

Research: New target for treating Huntington's and Parkinson's disease

Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted.

9 Jan 2014

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Although drugs have been developed that inhibit the imbalance of neurotransmitters in the brain - a condition which causes many brain disorders and nervous system diseases - the exact understanding of the mechanism by which these drugs work has not yet been fully understood.

8 Jan 2014

Toshiba’s MR technologies improve patient care, diagnostic accuracy

Clinicians can utilize MRI to diagnose more conditions with Toshiba America Medical Systems, Inc.'s advanced applications for its Vantage Titan™ MR systems.

3 Dec 2013

Screening for nonmotor symptoms in early Parkinson’s urged

Nonmotor symptoms have a substantial impact on the health-related quality of life of patients with early Parkinson’s disease, research shows.

14 Nov 2013

Researchers take a step forward in unravelling the causes of inherited intellectual disability

University of Adelaide researchers have taken a step forward in unravelling the causes of a commonly inherited intellectual disability, finding that a genetic mutation leads to a reduction in certain proteins in the brain.

14 Nov 2013

Professor receives $1.3M EUREKA grant to explore communication between cytoplasm and nucleus

University of Massachusetts Medical School Professor and Vice Chair of Neurobiology Vivian Budnik, PhD, has received a four-year, $1.3 million EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant from the National Institute of Neurological Disorders and Stroke to explore a novel mechanism of communication between the cytoplasm and the nucleus, called nuclear envelope budding, that may lead to new understandings for various tissue dystrophies and aging disorders.

8 Oct 2013

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.

30 Sep 2013

LCT successfully implants first patient with potential Parkinson's disease treatment

Living Cell Technologies Limited today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL – a potential treatment for Parkinson's disease.

20 Sep 2013

Scientists find link between early-onset Parkinson's and 22q11.2 deletion syndrome

Scientists at the Centre for Addiction and Mental Health (CAMH) and University Health Network (UHN) have found a new link between early-onset Parkinson's disease and a piece of DNA missing from chromosome 22. The findings help shed new light on the molecular changes that lead to Parkinson's disease.

10 Sep 2013

Identifying changes in handwriting could lead to early diagnosis of Parkinson's

Today's primary tool for diagnosing Parkinson's disease is the diagnostic ability of the physician, who can generally identify the clinical symptoms only when the disease is at a relatively advanced stage. A new joint study by researchers at the University of Haifa and Rambam Hospital that compared the handwriting of 40 sick and healthy subjects suggests an innovative and noninvasive method of diagnosing Parkinson's at a fairly early stage.